Hi kens. I think it is important to note that increase of new patients from Q4 to Q1 despite being a seasonly weaker quarter in conjunction with the improved discountuation rates means we might see a figure higher than that. For example if we could expect 4% patient growth (quarter on quarter) that's closer to 17% increase over a year due to compounding affect. I don't know if we'll hit 4% relative increase each quarter, but I would think 15% may be achievable with the 30% increase in sales force and the more stable existing cohort of patients.
- Forums
- ASX - By Stock
- Ann: DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.00%
!
$12.96

Hi kens. I think it is important to note that increase of new...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.96 |
Change
0.000(0.00%) |
Mkt cap ! $1.612B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 34 | $14.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.92 | 261 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 34 | 14.020 |
1 | 2 | 13.350 |
1 | 1000 | 13.000 |
2 | 219 | 12.960 |
1 | 172 | 12.950 |
Price($) | Vol. | No. |
---|---|---|
11.920 | 261 | 2 |
12.000 | 47 | 1 |
12.180 | 99 | 5 |
12.320 | 440 | 1 |
12.590 | 54 | 3 |
Last trade - 09.51am 17/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online